We’re thrilled to announce the publication of our first paper titled:
“Therapeutic drug monitoring of monoclonal antibodies in chronic inflammatory diseases: A snapshot of laboratories and applications across Europe”
This research, conducted in collaboration with the European Cooperation in Science and Technology (COST) action ENOTTA members, sheds light on the current landscape of therapeutic drug monitoring (TDM) for monoclonal antibodies in chronic inflammatory diseases across Europe.
Our study involved a comprehensive survey of laboratories, revealing valuable insights into:
- The prevalence of TDM for monoclonal antibodies
- The range of analytical methods employed by different labs
- Existing applications of TDM in clinical settings
This data paves the way for harmonization of analytical approaches and furthers the field of TDM for monoclonal antibodies. You can access the paper https://pubmed.ncbi.nlm.nih.gov/38278525/.
A huge thank you to the entire team and our collaborators at ENOTTA for this significant achievement!
#MonoclonalAntibodies #TDM #ChronicInflammation #Research #Europe #Collaboration
Feel free to comment below or reach out to discuss the findings in more detail!
